Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,001 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extragonadal germ cell tumors in Japan.
Ebi H, Nakata M, Tahara M, Igarashi T, Kawada K, Itoh K, Ueda R, Minami H. Ebi H, et al. Among authors: itoh k. Cancer Sci. 2003 Dec;94(12):1107-11. doi: 10.1111/j.1349-7006.2003.tb01408.x. Cancer Sci. 2003. PMID: 14662028 Free PMC article.
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Oct;100(10):1951-6. doi: 10.1111/j.1349-7006.2009.01247.x. Epub 2009 Jun 17. Cancer Sci. 2009. PMID: 19594547 Free PMC article. Clinical Trial.
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y; All Collaborators of the IDEC-C2B8 Study Group in Japan. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2010 Dec;101(12):2579-85. doi: 10.1111/j.1349-7006.2010.01703.x. Cancer Sci. 2010. PMID: 20942866 Free PMC article. Clinical Trial.
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8. Cancer Sci. 2011. PMID: 21645173 Free article. Clinical Trial.
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K. Watanabe T, et al. Among authors: itoh k. Cancer Sci. 2005 Dec;96(12):903-10. doi: 10.1111/j.1349-7006.2005.00120.x. Cancer Sci. 2005. PMID: 16367911 Free PMC article. Clinical Trial.
4,001 results